ZVRA — Zevra Therapeutics Share Price
Last trade - 00:00- $762.58m
- $561.97m
- $106.47m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 12.17 | ||
| PEG Ratio (f) | 0.27 | ||
| EPS Growth (f) | 84.22% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.71 | ||
| Price to Tang. Book | 3.91 | ||
| Price to Free Cashflow | 63.58 | ||
| Price to Sales | 6.24 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -2.35% | ||
| Return on Equity | 94.87% | ||
| Operating Margin | -4.44% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 28.65 | 10.16 | 27.46 | 23.61 | 106.47 | 146.45 | 201.44 | 51.62% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | +151.14 | +53.66 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Zevra Therapeutics, Inc. is a commercial-stage rare disease company with a late-stage pipeline committed to bringing therapeutics to people living with rare diseases. Its commercial products and active development assets are MIPLYFFA, Arimoclomol, OLPRUVA, and Celiprolol. Its lead product, Niemann-Pick disease type C (NPC), is a rare, progressive neurodegenerative disorder. NPC is an ultra-rare and progressive neurodegenerative disease characterized by an inability of the body to transport cholesterol and lipids inside of cells. OLPRUVA (sodium phenylbutyrate) for oral suspension is approved in the United States as adjunctive therapy to standard of care, which includes dietary management, for the chronic management of UCDs involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase, or argininosuccinic acid synthetase. Celiprolol is a selective adrenoceptor modulator (SAM). Celiprolol is approved in certain EU states for the treatment of hypertension and angina.
Directors
- Richard Pascoe CHM (57)
- Travis Mickle PRE (47)
- R. LaDuane Clifton CFO (48)
- Sven Guenther EVP (48)
- Timothy Sangiovanni VPR (37)
- Tamara Seymour DRC (63)
- Matthew Plooster IND (39)
- Joseph Saluri IND (54)
- David Tierney IND (57)
- Last Annual
- December 31st, 2025
- Last Interim
- March 31st, 2026
- Incorporated
- May 28th, 2014
- Public Since
- April 16th, 2015
- No. of Shareholders
- 91
- No. of Employees
- 61
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 59,115,084
- Address
- 1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION, 34747
- Web
- https://zevra.com/
- Phone
- +1 3219393416
- Auditors
- Ernst & Young LLP
Latest News for ZVRA
Upcoming Events for ZVRA
Q2 2026 Zevra Therapeutics Inc Earnings Release
Q3 2026 Zevra Therapeutics Inc Earnings Release
Similar to ZVRA
Alnylam Pharmaceuticals
NASDAQ Global Select Market
Amgen
NASDAQ Global Select Market
Amneal Pharmaceuticals
NASDAQ Global Select Market
Amphastar Pharmaceuticals,
NASDAQ Global Select Market
Arcutis Biotherapeutics
NASDAQ Global Select Market
FAQ
As of Today at 06:18 UTC, shares in Zevra Therapeutics are trading at $12.90. This share price information is delayed by 15 minutes.
Shares in Zevra Therapeutics last closed at $12.90 and the price had moved by +42.23% over the past 365 days. In terms of relative price strength the Zevra Therapeutics share price has outperformed the S&P500 Index by +13.16% over the past year.
The overall consensus recommendation for Zevra Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreZevra Therapeutics does not currently pay a dividend.
Zevra Therapeutics does not currently pay a dividend.
Zevra Therapeutics does not currently pay a dividend.
To buy shares in Zevra Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $12.90, shares in Zevra Therapeutics had a market capitalisation of $762.58m.
Here are the trading details for Zevra Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ZVRA
Based on an overall assessment of its quality, value and momentum Zevra Therapeutics is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Zevra Therapeutics is $28.25. That is 118.99% above the last closing price of $12.90.
Analysts covering Zevra Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of $0.85 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Zevra Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +42.36%.
As of the last closing price of $12.90, shares in Zevra Therapeutics were trading +34.49% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Zevra Therapeutics PE ratio based on its reported earnings over the past 12 months is 12.17. The shares last closed at $12.90.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Zevra Therapeutics' management team is headed by:
- Richard Pascoe - CHM
- Travis Mickle - PRE
- R. LaDuane Clifton - CFO
- Sven Guenther - EVP
- Timothy Sangiovanni - VPR
- Tamara Seymour - DRC
- Matthew Plooster - IND
- Joseph Saluri - IND
- David Tierney - IND